Investors > About us

Board of Directors

Investors > About us

Board of Directors

Our Board of Directors is composed by:

Steve Swinson

Chairman

Steve Swinson holds a PhD in electrical engineering from Manchester University in the United Kingdom and an MBA from the University of Chicago. Prior to joining Vexim’s board Steve Swinson was responsible for leading the Spine & Biologics business for Western Europe and Canada at Medtronic. He was previously International Vice President for Spine & Biologics. Previously at Medtronic, he was Vice President for Emerging Markets responsible for P&L and operating margins for all Medtronic product lines, covering a wide geography from South Asia including India, Africa, Middle East and Latin America. Steve Swinson has over 30 years’ experience in international business. He managed the indirect channel of distributors for Hewlett Packard Medical Products Group in Europe and was Vice President of Marquette Medical Systems for Asia Pacific. He also managed the Diagnostic X-ray business on global basis for GE Medical Systems in 2002.

Steve Swinson

Chairman

Steve Swinson holds a PhD in electrical engineering from Manchester University in the United Kingdom and an MBA from the University of Chicago. Prior to joining Vexim’s board Steve Swinson was responsible for leading the Spine & Biologics business for Western Europe and Canada at Medtronic. He was previously International Vice President for Spine & Biologics. Previously at Medtronic, he was Vice President for Emerging Markets responsible for P&L and operating margins for all Medtronic product lines, covering a wide geography from South Asia including India, Africa, Middle East and Latin America. Steve Swinson has over 30 years’ experience in international business. He managed the indirect channel of distributors for Hewlett Packard Medical Products Group in Europe and was Vice President of Marquette Medical Systems for Asia Pacific. He also managed the Diagnostic X-ray business on global basis for GE Medical Systems in 2002.

Dr. Philippe Pouletty

Truffle Capital representative

Philippe Pouletty is a Doctor of Medicine (Université Paris VI), immunologist, former intern with the Hospitals of Paris, a laureate of the Pasteur Institute (immunology) and a postdoctoral fellow at Stanford University. He is the inventor of 29 patents, including the second-most profitable for Stanford University, in life sciences. Philippe Pouletty is the Founder and Managing Director of Truffle Capital, a fund with 500 million euros of equity under management. He was the President of France Biotech, the French association of biotechnology companies, and former Vice-President of EuropaBio, the European association for bio-industries. He also founded three biotech companies in Europe and the United States, which generated market capitalization of over 800 million dollars, and is a member of the board of 12 biotech and medical device companies in Europe and North America (BMD, Carmat, Deinove, Innate Pharma, ITS, Neovacs, Pharnext, PlasmaPrime, Splicos, Symetis, Theraclion, Vexim and Wittycell). Philippe Pouletty was also responsible for several governmental initiatives in France, including the 1999 law that simplified company law (SAS), the “Plan Biotech 2002” to launch and develop biotechnology, and the Jeune Entreprise Innovante (Young Innovative Enterprise) status, which awards significant tax exemptions to tech companies.

Dr. Philippe Pouletty

Truffle Capital representative

Philippe Pouletty is a Doctor of Medicine (Université Paris VI), immunologist, former intern with the Hospitals of Paris, a laureate of the Pasteur Institute (immunology) and a postdoctoral fellow at Stanford University. He is the inventor of 29 patents, including the second-most profitable for Stanford University, in life sciences. Philippe Pouletty is the Founder and Managing Director of Truffle Capital, a fund with 500 million euros of equity under management. He was the President of France Biotech, the French association of biotechnology companies, and former Vice-President of EuropaBio, the European association for bio-industries. He also founded three biotech companies in Europe and the United States, which generated market capitalization of over 800 million dollars, and is a member of the board of 12 biotech and medical device companies in Europe and North America (BMD, Carmat, Deinove, Innate Pharma, ITS, Neovacs, Pharnext, PlasmaPrime, Splicos, Symetis, Theraclion, Vexim and Wittycell). Philippe Pouletty was also responsible for several governmental initiatives in France, including the 1999 law that simplified company law (SAS), the “Plan Biotech 2002” to launch and develop biotechnology, and the Jeune Entreprise Innovante (Young Innovative Enterprise) status, which awards significant tax exemptions to tech companies.

Douglas Beall

Chief of Services, Clinical Radiology of Oklahoma

Dr. Douglas P. Beall attended medical school at Georgetown University and completed his residency at The Johns Hopkins Hospital. Following completion of his residency, he was chief of interventional services at Sheppard Air Force Base. He then completed a fellowship in musculoskeletal radiology at the Mayo Clinic in Rochester, MN, where he was trained in joint and spine injection techniques before returning to the U.S. Air Force where he was division chief of the musculoskeletal section. In addition to his expertise in musculoskeletal imaging and interventional spine care, Dr. Beall is a diplomate of the American Academy of Pain and is actively involved in teaching and research. Dr. Beall has published more than 180 articles in peer-reviewed journals, has authored three textbooks and 11 textbook chapters and has given more than 200 invited lectures and scientific presentations.

Douglas Beall

Chief of Services, Clinical Radiology of Oklahoma

Dr. Douglas P. Beall attended medical school at Georgetown University and completed his residency at The Johns Hopkins Hospital. Following completion of his residency, he was chief of interventional services at Sheppard Air Force Base. He then completed a fellowship in musculoskeletal radiology at the Mayo Clinic in Rochester, MN, where he was trained in joint and spine injection techniques before returning to the U.S. Air Force where he was division chief of the musculoskeletal section. In addition to his expertise in musculoskeletal imaging and interventional spine care, Dr. Beall is a diplomate of the American Academy of Pain and is actively involved in teaching and research. Dr. Beall has published more than 180 articles in peer-reviewed journals, has authored three textbooks and 11 textbook chapters and has given more than 200 invited lectures and scientific presentations.

Marie-Laure Pochon

CEO of Acteon Group

Mrs. Marie-Laure Pochon has been Chief Executive Officer of the Acteon Group, since October 2014. From 2007 to 2012, she worked in Lundbeck where she notably served as Chief Executive of Lundbeck France; Regional Vice President for Western Europe and also Chief Operating Officer (Executive VP for Commercial Operations) for the whole Lundbeck Group. From 2012 to 2013, she was working with GN Store Nord where she was Senior Vice-President for Europe & Strategic Accounts. Marie-Laure Pochon worked during 30 years in the Pharmaceutical Industry, where she started in large US groups: MSD during 12 years and then Pfizer during 4 years. After this first period, she was appointed Managing Director in Schwarz Pharma (8 years) and then in Lundbeck (6 years). She served as an Executive Director in Lundbeck; as a Director in Mauna Kea Technologies SAS from June 2012 to June 2014 and was also part of the Leem Board during 6 years. Besides, she co-founded an association of pharmaceuticals companies (CRIP). By education, she holds an Engineer degree (ESPCI, Physics & Chemistry Paris) and a MBA for HEC Paris.

Marie-Laure Pochon

CEO of Acteon Group

Mrs. Marie-Laure Pochon has been Chief Executive Officer of the Acteon Group, since October 2014. From 2007 to 2012, she worked in Lundbeck where she notably served as Chief Executive of Lundbeck France; Regional Vice President for Western Europe and also Chief Operating Officer (Executive VP for Commercial Operations) for the whole Lundbeck Group. From 2012 to 2013, she was working with GN Store Nord where she was Senior Vice-President for Europe & Strategic Accounts. Marie-Laure Pochon worked during 30 years in the Pharmaceutical Industry, where she started in large US groups: MSD during 12 years and then Pfizer during 4 years. After this first period, she was appointed Managing Director in Schwarz Pharma (8 years) and then in Lundbeck (6 years). She served as an Executive Director in Lundbeck; as a Director in Mauna Kea Technologies SAS from June 2012 to June 2014 and was also part of the Leem Board during 6 years. Besides, she co-founded an association of pharmaceuticals companies (CRIP). By education, she holds an Engineer degree (ESPCI, Physics & Chemistry Paris) and a MBA for HEC Paris.

Bernard Belloc

Strategic Consultant for SKEMA Business School

Bernard Belloc holds a Ph.D. in Economic Sciences, a post-graduate doctorate in mathematical economics and econometrics, and a post-graduate professorial degree (“aggregation”) in law and economic sciences. He started his career as a professor at the Université de Bordeaux 1, then taught at the Université de Toulouse 1, which he presided between 1998 and 2003. A member of the French national council for universities (CNU) from 1992 to 1998, he was also a member of the board of Edufrance (2000-2001) and Vice-Chairman of the French university presidents conference (CPU) from 2000 to 2002. From 1990 to 1993, he was a member of various experts groups for the Ministry of Higher Education studying contracts with institutions. In 2002-2003, he was entrusted by Minister Luc Ferry with proposing a reform of the university professor and associate professor status. In parallel, Bernard Belloc was appointed to the Conseil économique et social Midi-Pyrénées (2002), the Haut comité éducation-économie-emploi (2001-2004) and a number of other councils and committees, including the Haut conseil de la coopération internationale (HCCI). In the 2000s, he joined a number of international missions in the United States and Asia. Bernard Belloc was a science and technology advisor for the French Embassy in China from 2005 to 2007. He was then appointed Advisor on Higher Education and Research by the French President. Since September 2012, he has held the position of Strategic Consultant for the SKEMA Business School.

Bernard Belloc

Strategic Consultant for SKEMA Business School

Bernard Belloc holds a Ph.D. in Economic Sciences, a post-graduate doctorate in mathematical economics and econometrics, and a post-graduate professorial degree (“aggregation”) in law and economic sciences. He started his career as a professor at the Université de Bordeaux 1, then taught at the Université de Toulouse 1, which he presided between 1998 and 2003. A member of the French national council for universities (CNU) from 1992 to 1998, he was also a member of the board of Edufrance (2000-2001) and Vice-Chairman of the French university presidents conference (CPU) from 2000 to 2002. From 1990 to 1993, he was a member of various experts groups for the Ministry of Higher Education studying contracts with institutions. In 2002-2003, he was entrusted by Minister Luc Ferry with proposing a reform of the university professor and associate professor status. In parallel, Bernard Belloc was appointed to the Conseil économique et social Midi-Pyrénées (2002), the Haut comité éducation-économie-emploi (2001-2004) and a number of other councils and committees, including the Haut conseil de la coopération internationale (HCCI). In the 2000s, he joined a number of international missions in the United States and Asia. Bernard Belloc was a science and technology advisor for the French Embassy in China from 2005 to 2007. He was then appointed Advisor on Higher Education and Research by the French President. Since September 2012, he has held the position of Strategic Consultant for the SKEMA Business School.

Vincent Gardès

Chief Executive Officer

Vincent Gardès holds a Bachelor of Arts in Business Administration from INSEEC Business School and a Post-Graduate Certificate in Leadership Capability from Glasgow Caledonian University. He speaks three languages (French, English and Spanish). Vincent Gardès began his career in 1995 at Stryker Spine as Product Manager for Europe. From 1996 to 1999, he held the position of Sales & Marketing Manager Knees & Spine at the Spanish subsidiary, Stryker Spain. Returning to France in 1999, he successively held the positions of Team Leader Hips for Stryker Europe, then Global Group Product Manager for Stryker Spine until 2002. At the end of 2002, Vincent Gardès joined the Medtronic Group, where he held the position of Spine Division Director for Europe. In 2004, he was promoted to Business Unit Manager Spine & Biologics, France, then in 2007, to Business Director for Southern Europe. Since September 2008, Vincent Gardès was CEO of CR Bard for Spain and Portugal, based in Barcelona. Starting in July 2011, he consulted for Vexim on behalf of Truffle Capital. Vincent Gardès was appointed Chief Executive Officer of Vexim in December 2011.

Vincent Gardès

Chief Executive Officer

Vincent Gardès holds a Bachelor of Arts in Business Administration from INSEEC Business School and a Post-Graduate Certificate in Leadership Capability from Glasgow Caledonian University. He speaks three languages (French, English and Spanish). Vincent Gardès began his career in 1995 at Stryker Spine as Product Manager for Europe. From 1996 to 1999, he held the position of Sales & Marketing Manager Knees & Spine at the Spanish subsidiary, Stryker Spain. Returning to France in 1999, he successively held the positions of Team Leader Hips for Stryker Europe, then Global Group Product Manager for Stryker Spine until 2002. At the end of 2002, Vincent Gardès joined the Medtronic Group, where he held the position of Spine Division Director for Europe. In 2004, he was promoted to Business Unit Manager Spine & Biologics, France, then in 2007, to Business Director for Southern Europe. Since September 2008, Vincent Gardès was CEO of CR Bard for Spain and Portugal, based in Barcelona. Starting in July 2011, he consulted for Vexim on behalf of Truffle Capital. Vincent Gardès was appointed Chief Executive Officer of Vexim in December 2011.

Antoine Pau

Pharmacist and ESSEC graduate

Antoine Pau started his career at Novartis Pharma in the Business Planning Analysis department (Oncology Business Unit). He then joined Mazars as financial auditor where he worked for three years managing the legal audits of pharmaceutical and biotech companies, as well as investments funds, and also participated in the financial due diligence process for tech companies in the Transaction Services department. He joined Truffle Capital in 2008, where he holds the position of Life Sciences Investment Director. He is also a lecturer at Science Po in Paris.

Antoine Pau

Pharmacist and ESSEC graduate

Antoine Pau started his career at Novartis Pharma in the Business Planning Analysis department (Oncology Business Unit). He then joined Mazars as financial auditor where he worked for three years managing the legal audits of pharmaceutical and biotech companies, as well as investments funds, and also participated in the financial due diligence process for tech companies in the Transaction Services department. He joined Truffle Capital in 2008, where he holds the position of Life Sciences Investment Director. He is also a lecturer at Science Po in Paris.

&nsbp

&nsbp

Press Releases & Newsletters

Capital Structure